UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
10-K/A
Amendment
No. 1
[X] ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR
THE ANNUAL PERIOD ENDED MARCH 31, 2021
OR
[ ] TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR
THE TRANSITION PERIOD FROM _______________ TO _______________
COMMISSION
FILE NUMBER: 001-15697
| ELITE
PHARMACEUTICALS, INC. |
| (Exact
Name of Registrant as Specified in Its Charter) |
| NEVADA |
|
22-3542636 |
(State
or other jurisdiction of
incorporation
or organization) |
|
(I.R.S.
Employer
Identification
No.) |
165
LUDLOW AVENUE
NORTHVALE,
NEW JERSEY |
|
07647 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
| (201)
750-2646 |
(Registrant’s
telephone number, including area code)
Securities
Registered pursuant to Section 12(g) of the Act: |
| Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 per share |
|
ELTP |
|
OTCQB |
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ ] No [X]
Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Securities Exchange Act
of 1934. Yes [ ] No [X]
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes [X] No [ ]
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”,
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large
accelerated filer |
[ ] |
Accelerated
filer |
[ ] |
| Non-accelerated
filer |
[X] |
Smaller
reporting company |
[X] |
| |
|
Emerging
growth company |
[ ] |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Indicate
by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered
public accounting firm that prepared or issued its audit report. [ ]
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]
The
aggregate market value of Common Stock held by non-affiliates at September 30, 2020, the last business day of the registrant’s
most recently completed second fiscal quarter was $56,138,409.
The
number of shares of the registrant’s Common Stock outstanding as of June 7, 2021 was 1,009,176,752.
EXPLANATORY
NOTE
This
Amendment No. 1 on Form 10-K/A (Amendment No. 1) is being filed to amend our Annual Report on Form 10-K for the annual period ended March
31, 2021 (Original Filing), filed with the U.S. Securities and Exchange Commission on June 14, 2021 (Original Filing Date). The sole
purpose of this Amendment No. 1 is to correct a typographical error in the previously filed report located in Item 5 of Part II, Market
for Company’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities, which inadvertently stated
the last sale price of Common Stock as reported by the OTCBB as “$0.60” rather than “$0.06”.
Except
as described above, no changes have been made to the Original Filing, and this Amendment No. 1 does not modify, amend or update in any
way any of the financial or other information contained in the Original Filing. This Amendment No. 1 does not reflect events that may
have occurred subsequent to the Original Filing Date.
Pursuant
to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 also contains the inclusion of the certifications
required under Section 302 of the Sarbanes-Oxley Act of 2002 in Item 15 of Part IV. Because no financial statements have been included
in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation
S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. This Amendment No. 1 does not include new certifications under Section
906 of the Sarbanes-Oxley Act of 2002 because no financial statements are included in this Amendment No. 1.
PART
IV
ITEM
15. EXHIBITS, FINANCIAL STATEMENTS AND SCHEDULES
| Exhibit
No. |
|
Description |
| |
|
|
| 3.1(a)
|
|
Articles
of Incorporation of Elite-Nevada, incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC on
January 9, 2012. |
| |
|
|
| 3.1(b)
|
|
Certificate
of Designations of the Series G Convertible Preferred Stock as filed with the Secretary of State of the State of Nevada on April
18, 2013, incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K, dated April 18, 2013 and filed with the SEC
on April 22, 2013. |
| |
|
|
| 3.1(c)
|
|
Certificate
of Designation of the Series H Junior Participating Preferred Stock, incorporated by reference to Exhibit 2 (contained in Exhibit
1) to the Registration Statement on Form 8-A filed with the SEC on November 15, 2013. |
| |
|
|
| 3.1(d)
|
|
Certificate
of Designations of the Series I Convertible Preferred Stock as filed with the Secretary of State of the State of Nevada on February
6, 2014, incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, dated February 6, 2014 and filed with the SEC
on February 7, 2014. |
| |
|
|
| 3.1(e)
|
|
Certificate
of Designations of the Series J Convertible Preferred Stock as filed with the Secretary of State of the State of Nevada on May 3,
2017, incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, dated April 28, 2017 and filed with the SEC on
April 28, 2017. |
| |
|
|
| 3.1(f)
|
|
Certificate
of Amendment to Articles of Incorporation, incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, dated June
24, 2020 and filed with the SEC on June 24, 2020. |
| |
|
|
| 3.2(a)
|
|
Amended
and Restated By-Laws of the Company, incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K dated April 23, 2020
and filed with the SEC on April 23, 2020. |
| |
|
|
| 4.1
|
|
Form
of specimen certificate for Series G Convertible Preferred Stock of the Company, incorporated by reference to Exhibit 4.2 to the
Current Report on Form 8-K, dated April 18, 2013 and filed with the SEC on April 22, 2013. |
| |
|
|
| 4.2
|
|
Form
of specimen certificate for Series I Convertible Preferred Stock of the Company, incorporated by reference to Exhibit 4.2 to the
Current Report on Form 8-K, dated February 6, 2014 and filed with the SEC on February 7, 2014. |
| |
|
|
| 4.3
|
|
Rights
Agreement, dated as of November 15, 2013, between the Company and American Stock Transfer & Trust Company, LLC., incorporated
by reference to Exhibit 1 to the Registration Statement on Form 8-A filed with the SEC on November 15, 2013. |
| |
|
|
| 4.4
|
|
Form
of Series H Preferred Stock Certificate, incorporated by reference to Exhibit 1 to the Registration Statement on Form 8-A filed with
the SEC on November 15, 2013. |
| |
|
|
| 4.5
|
|
Warrant
to purchase shares of Common Stock issued to Nasrat Hakim dated April 28, 2017 incorporated by reference to Exhibit 4.1 to the Current
Report on Form 8-K, dated April 28, 2017, and filed with the SEC on April 28, 2017. |
| |
| 4.6 |
|
Description
of Common Stock, incorporated by reference to Exhibit 4.6 to the Report 10-K filed in June 2020. |
| |
|
|
| 10.1 |
|
Elite
Pharmaceuticals, Inc. 2014 Equity Incentive Plan, incorporated by reference to Appendix B to the Company’s Definitive Proxy
Statement for its Annual Meeting of Shareholders, filed with the SEC on April 3, 2014. |
| |
|
|
| 10.2 |
|
Form
of Confidentiality Agreement (corporate), incorporated by reference to Exhibit 10.7 to the Form SB-2. |
| |
|
|
| 10.3 |
|
Form
of Confidentiality Agreement (employee), incorporated by reference to Exhibit 10.8 to the Form SB-2. |
| |
|
|
| 10.4 |
|
Loan
Agreement, dated as of August 15, 2005, between New Jersey Economic Development Authority (“NJEDA”) and the Company,
incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, dated August 31, 2005 and filed with the SEC on September
6, 2005. |
| |
|
|
| 10.5 |
|
Series
A Note in the aggregate principal amount of $3,660,000.00 payable to the order of the NJEDA, incorporated by reference to Exhibit
10.2 to the Current Report on Form 8-K, dated August 31, 2005 and filed with the SEC on September 6, 2005. |
| |
|
|
| 10.6 |
|
Series
B Note in the aggregate principal amount of $495,000.00 payable to the order of the NJEDA, incorporated by reference to Exhibit 10.3
to the Current Report on Form 8-K, dated August 31, 2005 and filed with the SEC on September 6, 2005. |
| |
|
|
| 10.7 |
|
Mortgage
from the Company to the NJEDA, incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K, dated August 31, 2005
and filed with the SEC on September 6, 2005. |
| |
|
|
| 10.8 |
|
Indenture
between NJEDA and the Bank of New York as Trustee, dated as of August 15, 2005, incorporated by reference to Exhibit 10.5 to the
Current Report on Form 8-K, dated August 31, 2005 and filed with the SEC on September 6, 2005. |
| |
|
|
| 10.13 |
|
Employment
Agreement, dated as of November 13, 2009, by and between the Company and Carter J. Ward, incorporated by reference to Exhibit 10.2
to the Quarterly Report on Form 10-Q, for the period ending September 30, 2009 and filed with the SEC on November 16, 2009.+ |
| |
|
|
| 10.15 |
|
License
Agreement, dated as of September 10, 2010, by and among Precision Dose Inc. and the Company, incorporated by reference to Exhibit
10.8 to the Quarterly Report on Form 10-Q, for the period ended September 30, 2010 and filed with the SEC on November 15, 2010 (Confidential
Treatment granted with respect to portions of the Agreement). |
| 10.16 |
|
Manufacturing
and Supply Agreement, dated as of September 10, 2010, by and among Precision Dose Inc. and the Company, incorporated by reference
to Exhibit 10.9 to the Quarterly Report on Form 10-Q, for the period ended September 30, 2010 and filed with the SEC on November
15, 2010 (Confidential Treatment granted with respect to portions of the Agreement). |
| |
|
|
| 10.17 |
|
August
1, 2013 Employment Agreement with Nasrat Hakim, incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K, dated
August 1, 2013 and filed with the SEC on August 5, 2013.+ |
| |
|
|
| 10.18 |
|
August
1, 2013 Mikah LLC Asset Purchase Agreement, incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K/A, dated
August 1, 2013 and filed with the SEC on August 30, 2018. (Confidential Treatment granted with respect to portions of the Agreement). |
| |
|
|
| 10.19 |
|
August
1, 2013 Secured Convertible Note from the Company to Mikah Pharma LLC., incorporated by reference to Exhibit 10.2 to the Current
Report on Form 8-K, dated August 1, 2013 and filed with the SEC on August 5, 2013. |
| |
|
|
| 10.20 |
|
August
1, 2013 Security Agreement from the Company to Mikah Pharma LLC., incorporated by reference to Exhibit 10.3 to the Current Report
on Form 8-K, dated August 1, 2013 and filed with the SEC on August 5, 2013. |
| |
|
|
| 10.21 |
|
October
15, 2013 Hakim Credit Line Agreement, incorporated by reference to Exhibit 10.16 to the Quarterly Report on Form 10-Q for the period
ended September 30, 2013. |
| |
|
|
| 10.22 |
|
October
2, 2013 Manufacturing and Licensing Agreement with Epic Pharma LLC, incorporated by reference to Exhibit 10.17 to the Amended Quarterly
Report on Form 10-Q/A for the period ended September 30, 2013 and filed with the SEC on April 25, 2014. Confidential Treatment granted
with respect to portions of the Agreement. |
| |
|
|
| 10.23 |
|
February
7, 2014 Amendment to Secured Convertible Note from the Company to Mikah, incorporated by reference to Exhibit 10.1 to the Current
Report on Form 8-K, dated February 7, 2014 and filed with the SEC on February 7, 2014. |
| |
|
|
| 10.24 |
|
Employment
Agreement with Dr. G. Kenneth Smith, dated October 20, 2014, incorporated by reference to Exhibit 10.82 to the Quarterly Report on
Form 10-Q for the period ended September 30, 2014 and filed with the SEC on November 14, 2014.+ |
| |
|
|
| 10.25 |
|
January
28, 2015 First Amendment to the Loan Agreement between Nasrat Hakim and Elite Pharmaceuticals dated October 15, 2013, incorporated
by reference to Exhibit 10.83 to the Quarterly Report on Form 10-Q for the period ended December 31, 2014 and filed with the SEC
on February 17, 2015. |
| |
|
|
| 10.26 |
|
January
28, 2015 Termination of Development and License Agreement for Mikah-001 between Elite Pharmaceuticals, Inc. and Mikah Pharma LLC
and Transfer of Payment, incorporated by reference to Exhibit 10.84 to the Quarterly Report on Form 10-Q for the period ended December
31, 2014 and filed with the SEC on February 17, 2015. |
| |
|
|
| 10.28 |
|
Amendment
No. 1 to Hakim Employment Agreement, incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC
on January 29, 2016. |
| |
|
|
| 10.29 |
|
August
24, 2016 Master Development and License Agreement between Elite and SunGen Pharma LLC. incorporated by reference to Exhibit 10.44
to the Quarterly Report on Form 10-Q for the period ended September 30, 2016 and filed with the SEC on November 9, 2016. (Confidential
Treatment granted with respect to portions of the Agreement). |
| 10.30 |
|
Purchase
Agreement between the Company and Lincoln Park Capital LLC dated July 8, 2020, incorporated by reference to Exhibit 10.1 to the Current
Report on Form 8-K, dated July 9, 2020 and filed with the SEC on July 9, 2020. |
| |
|
|
| 10.31 |
|
Registration
Rights Agreement between the Company and Lincoln Park Capital LLC dated July 8, 2020, incorporated by reference to Exhibit 10.2 to
the Current Report on Form 8-K, dated July 9, 2020 and filed with the SEC on July 9, 2020. |
| |
|
|
| 10.33 |
|
May
2017 Trimipramine Acquisition Agreement from Mikah Pharma, incorporated by reference to Exhibit 10.50 to the Annual Report on Form
10-K, for the period ended March 31, 2017 and filed with the SEC on June 14, 2017. |
| |
|
|
| 10.34 |
|
May
2017 Secured Promissory Note from the Company to Mikah Pharma, incorporated by reference to Exhibit 10.51 to the Annual Report on
Form 10-K, for the period ended March 31, 2017 and filed with the SEC on June 14, 2017. |
| |
|
|
| 10.35 |
|
May
2017 Security Agreement between the Company to Mikah Pharma, incorporated by reference to Exhibit 10.52 to the Annual Report on Form
10-K, for the period ended March 31, 2017 and filed with the SEC on June 14, 2017. |
| |
|
|
| 10.36 |
|
May
2017 Assignment of Supply and Distribution Agreement between Dr. Reddy’s Laboratories and Mikah Pharma, incorporated by reference
to Exhibit 10.53 to the Annual Report on Form 10-K, for the period ended March 31, 2017 and filed with the SEC on June 14, 2017. |
| |
|
|
| 10.37 |
|
May
2017 Assignment of Manufacturing and Supply Agreement between Epic and Mikah Pharma, incorporated by reference to Exhibit 10.54 to
the Annual Report on Form 10-K, for the period ended March 31, 2017 and filed with the SEC on June 14, 2017. |
| |
|
|
| 10.38 |
|
Supply
and Distribution Agreement between Dr. Reddy’s Laboratories and Mikah Pharma, incorporated by reference to Exhibit 10.55 to
the Annual Report on Form 10-K, for the period ended March 31, 2017 and filed with the SEC on June 14, 2017. (Confidential Treatment
granted with respect to portions of the Agreement). |
| |
|
|
| 10.39 |
|
Manufacturing
and Supply Agreement between Epic and Mikah Pharma, incorporated by reference to Exhibit 10.56 to the Annual Report on Form 10-K,
for the period ended March 31, 2017 and filed with the SEC on June 14, 2017. (Confidential Treatment granted with respect to portions
of the Agreement). |
| |
|
|
| 10.40 |
|
Master
Development and License Agreement For Products Between Elite Pharmaceuticals, Inc. And SunGen dated July 6, 2017, incorporated by
reference to Exhibit 10.57 to the Quarterly Report on Form 10-Q for the period ended June 30, 2017 and filed with the SEC on August
9, 2017. (Confidential Treatment granted with respect to portions of the Agreement). |
| |
|
|
| 10.41 |
|
First
Amendment to Master Development And License Agreement For Products Between Elite Pharmaceuticals, Inc. and SunGen Pharma, LLC, incorporated
by reference to Exhibit 10.59 to the Quarterly Report on Form 10-Q for the period ended June 30, 2017 and filed with the SEC on August
9, 2017. (Confidential Treatment granted with respect to portions of the Agreement). |
| |
|
|
| 10.42 |
|
Second
Amendment to Master Development And License Agreement For Products Between Elite Pharmaceuticals, Inc. and SunGen Pharma, LLC, incorporated
by reference to Exhibit 10.58 to the Quarterly Report on Form 10-Q for the period ended June 30, 2017 and filed with the SEC on August
9, 2017. (Confidential Treatment granted with respect to portions of the Agreement). |
| 10.45 |
|
License,
Supply And Distribution Agreement effective March 6, 2019 by and between Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc.
and Lannett Company, Inc., USA, incorporated by reference to Exhibit 10.45 to the Quarterly Report on Form 10-Q, for the period ended
December 31, 2019 and filed with the SEC on February 10, 2020. (Portions of this Agreement have been redacted in compliance with
Regulation S-K Item 601(b)(10)). |
| |
|
|
| 10.46 |
|
License,
Supply and Distribution Agreement effective April 9, 2019 by and between Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc.
and Lannett Company, Inc., USA, incorporated by reference to Exhibit 10.49 to the Annual Report on Form 10-K for the period ended
March 31, 2019 and filed with the SEC on June 21, 2019 (portions of this Agreement have been redacted in compliance with Regulation
S-K Item 601(b)(10)). |
| |
|
|
| 10.47 |
|
License,
Supply and Distribution Agreement effective March 6, 2019 by and between Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc.
and Lannett Company, Inc., USA, incorporated by reference to Exhibit 10.50 to the Annual Report on Form 10-K for the period ended
March 31, 2019 and filed with the SEC on June 21, 2019 (portions of this Agreement have been redacted in compliance with Regulation
S-K Item 601(b)(10)). |
| |
|
|
| 10.48 |
|
Development
Agreement effective December 3, 2018 by and between Mikah Pharma LLC and Elite Laboratories, Inc., incorporated by reference to Exhibit
10.51 to the Annual Report on Form 10-K for the period ended March 31, 2019 and filed with the SEC on June 21, 2019 (portions of
this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)). |
| |
|
|
| 10.49 |
|
Asset
Purchase Agreement dated November 13, 2019 by and between the Company and Nostrum Laboratories Inc. , incorporated by reference to
Exhibit 10.49 to the Quarterly Report on Form 10-Q, for the period ended December 31, 2019 and filed with the SEC on February 10,
2020. |
| |
|
|
| 10.50 |
|
January
2, 2020 Amendment to the Glenmark Pharmaceuticals Inc. USA License, Supply and Distribution Agreement, incorporated by reference
to Exhibit 10.50 to the Quarterly Report on Form 10-Q, for the period ended December 31, 2019 and filed with the SEC on February
10, 2020. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)). |
| |
|
|
| 10.51 |
|
Asset
Purchase Agreement executed January 16, 2020 by and between the Company and Nostrum Laboratories Inc., incorporated by reference
to Exhibit 10.49 to the Quarterly Report on Form 10-Q, for the period ended December 31, 2019 and filed with the SEC on February
10, 2020. |
| |
|
|
| 10.52 |
|
Employment
Agreement with Douglas Plassche, incorporated by reference to Exhibit 10.52 to the Annual Report on Form 10-K, for the period ended
March 31, 2021 and filed with the SEC on June 14, 2021+ |
| |
|
|
| 10.53 |
|
June
21, 2019 Retention Agreement with Douglas Plassche, incorporated by reference to Exhibit 10.53 to the Annual Report on Form 10-K,
for the period ended March 31, 2021 and filed with the SEC on June 14, 2021+ |
| |
|
|
| 10.54 |
|
July
29, 2019 Amendment To The License, Supply And Distribution Agreement Between Elite Pharmaceuticals, Inc./Elite Laboratories, Inc.
And Lannett Company, Inc. (Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)). |
| |
|
|
| 21 |
|
Subsidiaries of the Company, incorporated by reference to Exhibit 21 to the Annual Report on Form 10-K, for the period ended March 31, 2019 and filed with the SEC on June 21, 2019. |
| |
|
|
| 23.1 |
|
Consent of Buchbinder Tunick & Company LLP, Independent Registered Public Accounting Firm, incorporated by reference to Exhibit 23.1 to the Annual Report on Form 10-K, for the period ended March 31, 2021 and filed with the SEC on June 14, 2021 |
| |
|
|
| 31.1* |
|
Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a) |
| 31.2* |
|
Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a) |
| |
|
|
| 32.1** |
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, incorporated by reference to Exhibit 32.1 to the Annual Report on Form 10-K, for the period ended March 31, 2021 and filed with the SEC on June 14, 2021 |
| |
|
|
| 32.2** |
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, incorporated by reference to Exhibit 32.2 to the Annual Report on Form 10-K, for the period ended March 31, 2021 and filed with the SEC on June 14, 2021 |
| |
|
|
| 101.INS* |
|
XBRL
Instance Document |
| |
|
|
| 101.SCH* |
|
XBRL
Taxonomy Schema Document |
| |
|
|
| 101.CAL* |
|
XBRL
Taxonomy Extension Calculation Linkbase Document |
| |
|
|
| 101.DEF* |
|
XBRL
Taxonomy Extension Definition Linkbase Document |
| |
|
|
| 101.LAB* |
|
XBRL
Taxonomy Extension Label Linkbase Document |
| |
|
|
| 101.PRE* |
|
XBRL
Taxonomy Extension Presentation Linkbase Document |
| |
|
|
| 104 |
|
Cover
Page Interactive Data File |
| + |
Indicates
management contract or compensatory plan or arrangement. |
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
| |
ELITE
PHARMACEUTICALS, INC. |
| |
|
|
| Dated:
June 22 2021 |
By: |
/s/
Nasrat Hakim |
| |
|
Nasrat
Hakim |
| |
|
Chief
Executive Officer |
| |
|
|
| Dated:
June 22, 2021 |
By: |
/s/
Marc Bregman |
| |
|
Marc
Bregman |
| |
|
Chief
Financial Officer |
